MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, J.
Right arrow Articles by Jacobson, K. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.
Right arrow Articles by Jacobson, K. A.

Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition

J Kim, Q Jiang, M Glashofer, S Yehle, J Wess and KA Jacobson

Molecular Recognition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

The A2a adenosine receptor, a member of the G protein-coupled receptor family, is important in the regulation of dopaminergic pathways of the brain and in platelet and cardiovascular functions. In this study, the role of extracellular loops in ligand binding to the human A2a receptor was explored through site-directed mutagenesis. Four glutamate/aspartate residues (Glu151, Glu161, Glu169, and Asp170) in the second extracellular loop (E2) and a cysteine residue (Cys262) in the third extracellular loop (E3) were individually replaced with alanine and other amino acids. A proline residue (Pro173) in E2 was mutated to arginine, the homologous amino acid in A3 receptors. The binding properties of the resultant mutant receptors were determined in transfected COS-7 cells. The mutant receptors were tagged at their amino terminus with a hemagglutinin epitope, thus allowing their detection in the plasma membrane with immunological techniques. High affinity specific binding of [3H]2-[4-[(2-carboxyethyl)phenyl]ethyl- amino]-5'-N-ethylcarboxamidoad eno sine (15 nM) and [3H]8-[4-[[[[2- aminoethyl)-amino]carbonyl]methyl]oxy]phenyl]-1,3- dipropylxanthine (4nM), an A2a agonist and antagonist, respectively, was not observed with four of the mutant receptors, E151A, E151Q, E151D, and E169A, although they were well expressed at the cell surface. The E151A and E169A mutant receptors showed nearly full stimulation of adenylyl cyclase at approximately 10(3)-fold higher concentrations of 2-[4-[(2- carboxyethyl)phenyl]ethyl-amino]-5'-N-ethylcarboxamidoadenosine . The E161A mutant receptor showed as increase in affinity for the nonxanthine adenosine antagonist 9-chloro-2-(furyl)[1,2,4]triazolo[1,5- c]quinazolin-5-amine(6 fold) but not for other ligands. An E169Q mutant gained affinity (5-22 fold) for adenosine derivatives (agonists) substituted at N6 but not at C2 or C5' positions. Mutant receptors D170K and P173R were similar to wild-type receptors in binding of both agonist and antagonist radioligands. A C262G mutant also resembled the wild-type receptor in radioligand binding, indicating that a potential disulfide bridge with another cysteine residue in proximity is not required for the structural integrity of the receptor. Our data suggest that certain amino acids in the second extracellular loop may be directly or indirectly involved in ligand binding.

Volume 49, Issue 4, pp. 683-691, 04/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Strasser, H.-J. Wittmann, and R. Seifert
Ligand-Specific Contribution of the N Terminus and E2-Loop to Pharmacological Properties of the Histamine H1-Receptor
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 783 - 791.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Lan, C. J. DuRand, M. M. Teeter, and K. A. Neve
Structural Determinants of Pharmacological Specificity Between D1 and D2 Dopamine Receptors
Mol. Pharmacol., January 1, 2006; 69(1): 185 - 194.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Tunaru, J. Lattig, J. Kero, G. Krause, and S. Offermanns
Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G)
Mol. Pharmacol., November 1, 2005; 68(5): 1271 - 1280.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Kukkonen, M. Perakyla, K. E. O. Akerman, and J. Nasman
Muscarinic Toxin 7 Selectivity Is Dictated by Extracellular Receptor Loops
J. Biol. Chem., December 3, 2004; 279(49): 50923 - 50929.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Shi and J. A. Javitch
The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice
PNAS, January 13, 2004; 101(2): 440 - 445.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
B. B. Fredholm, A. P. IJzerman, K. A. Jacobson, K.-N. Klotz, and J. Linden
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Pharmacol. Rev., December 1, 2001; 53(4): 527 - 552.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Hoffmann, S. Moro, R. A. Nicholas, T. K. Harden, and K. A. Jacobson
The Role of Amino Acids in Extracellular Loops of the Human P2Y1 Receptor in Surface Expression and Activation Processes
J. Biol. Chem., May 21, 1999; 274(21): 14639 - 14647.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Audoly and R. M. Breyer
The Second Extracellular Loop of the Prostaglandin EP3 Receptor Is an Essential Determinant of Ligand Selectivity
J. Biol. Chem., May 23, 1997; 272(21): 13475 - 13478.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics